Abstract
Intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) drugs has become the standard treatment for exudative age-related macular degeneration (AMD). However, there are some patients who do not have a sufficient response to the treatment, and some patients fail to respond to those drugs. The mechanisms of non-response to the treatment in these cases are poorly understood. These may be associated with wAMD types, vitreomacular abnormity, genetic factors, and tachyphylaxis, etc. Ophthalmologists should pay attention to those non-responders and give them the correct treatment, avoid the anti-VEGF drugs abuse and explore the best personalized treatment for those patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
